ArticleJournal of clinical hypertension (Greenwich, Conn.)2022
Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Safety and efficacy of angiotensin receptor neprilysin inhibitor in improving cardiac function and blood pressure in dialysis patients.Frontiers in medicine · 2024Pooled it
- I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology.Jornal brasileiro de nefrologiaGuideline
- Dose reduction and discontinuation of sacubitril/valsartan over time in patients undergoing maintenance hemodialysis.Frontiers in cardiovascular medicine · 2026Article
- Highlights of the 2026 Korean Society of Hypertension guidelines for the management of hypertension: what's new and what has changed.Clinical hypertension · 2026Review
- Resistant and Apparently Resistant Hypertension in Peritoneally Dialyzed Patients.Journal of clinical medicine · 2025Review
- Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study.PloS one · 2025Article
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India.Cardiology and therapy · 2024Review
- Myocardial work in chronic kidney disease: insights from the CPH-CKD ECHO Study.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Review
- Effect of sacubitril valsartan on heart failure with mid-range or preserved ejection fraction in patients on maintenance hemodialysis: real-world experience in a single-center, prospective study.BMC cardiovascular disorders · 2024Article
- Systematic Review of Cardiovascular Benefits and Safety of Sacubitril-Valsartan in End-Stage Kidney Disease.Kidney international reports · 2024Article
- Fatigue in Patients Receiving Maintenance Hemodialysis: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Review
- Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2023Article
- Comparative analysis of sacubitril/valsartan and losartan potassium in the treatment of hypertension: efficacy, adverse reactions, and observations.American journal of translational research · 2023Article
- The history and mystery of sacubitril/valsartan: From clinical trial to the real world.Frontiers in cardiovascular medicine · 2023Review
- Sacubitril/Valsartan in the Treatment of Resistant Hypertension: Raising Star or Illusion?Journal of clinical medicine · 2022Article
- Can myocardial work help in the therapy of resistant hypertension?Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
- Effects of Sacubitril/Valsartan on resistant hypertension and myocardial work in hemodialysis patients.Journal of clinical hypertension (Greenwich, Conn.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidences have confirmed the effect of Sacubitril/Valsartan (SV) on antihypertension and cardiac protection in general population. However, there was no prospective study about the effect and safety of SV on resistant hypertension and myocardial work in hemodialysis patients. In this single-center, prospective, before-after study, enrolled patients were endured with resistant hypertension for more than 6 months. Participants were initially instructed to take SV 50 mg twice daily, and the dosage was gradually increased up to 100 mg twice daily. The primary outcomes were blood pressure (BP) control, N-terminal pro-B-type natriuretic peptide (NT-proBNP), myocardial work (MW), fatigue and life quality. In addition, the adverse events were also recorded in this cohort. A total of 18 patients (34-64 years old) was finally enrolled and completed in this study. The SV-based regimen provided significantly mean sitting systolic BP (msSBP) and mean sitting diastolic BP (msDBP) reductions from baseline (-20.7/-8.3 mm Hg), respectively. The cardiac remodeling parameters were partially improved. Compared to the baseline, NT-proBNP was significantly reduced at week 4 (8119.50 [3710.75, 29300] pg/ml to 7216.50 [4124.75, 17455.00] pg/ml, p = .046), which was much lower at week 12 (3130.50 [2244.50, 9565.70] pg/ml, p = .037). Global MW index was higher at week 12 compared to the baseline (p = .026). MW efficiency was also improved accordingly compared to the baseline, even though the statistical difference was not significant (p = .226). Life quality and fatigue were improved at week 12 compared to the baseline (all p = .000). There was no serious adverse events were observed. SV safely and effectively controlled resistant hypertension and improved MW as well as life quality in hemodialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.